Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO

Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192.

(2017) H. Mackay et al.   JOURNAL OF CLINICAL ONCOLOGY

Hormone therapy plus temsirolimus for endometrial carcinoma (EC): Gynecologic Oncology Group trial #248.

(2017) G. F. Fleming et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

(2012) Thomas Bachelot et al.   JOURNAL OF CLINICAL ONCOLOGY

Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas

(2012) Keiko Shoji et al.   PLoS One

Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2011) N. Colombo et al.   ANNALS OF ONCOLOGY

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

(2011) Andrew X. Zhu et al.   CANCER

A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas

(2011) Meghan L. Rudd et al.   CLINICAL CANCER RESEARCH

PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors

(2011) Bożena Konopka et al.   HUMAN PATHOLOGY

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

(2011) Amit M. Oza et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes

(2011) Patrick Schöffski et al.   LANCET ONCOLOGY

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

(2010) Brian M. Slomovitz et al.   CANCER

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Expression profiling of 22 genes involved in the PI3K–AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations

(2010) Lluis Catasus et al.   MODERN PATHOLOGY

Concomitant PI3K–AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis

(2009) Lluis Catasus et al.   MODERN PATHOLOGY

Carboplatin and paclitaxel in advanced or metastatic endometrial cancer

(2008) D. Pectasides et al.   GYNECOLOGIC ONCOLOGY